The next generation of the nation’s only anthrax vaccine will be made in Lansing, an executive for Emergent BioSolutions Inc. said Tuesday.
There won’t be any new jobs as a direct result of the $29 million federal contract Emergent received earlier this month for production of the new drug, Adam Havey, president of the company’s biodefense division, said. But the new version of the vaccine will help keep current employees working.
The Tech Council of Maryland presents a Lifetime Achievement Award each year to an individual who has made outstanding contributions to the success of the community. This year, we are expanding our award categories and will be recognizing three outstanding individuals in the fields of technology, life science, and education. The 2015 honorees will be:
Please mark your calendar to honor these individuals at a celebratory dinner on February 19, 2015 at the Bethesda North Marriott Hotel and Conference Center.
GlaxoSmithKline has just launched a $5 million Innovation Challenge Fund to advance open-access technology in the bioelectronics space.
The funding’s aimed toward biz-savvy academics and startups that are working to create a new class of treatments that aren’t necessarily pills or injections, but rather are mini implantable devices. GSK says:”The hope is that these devices could be programmed to read and correct the electrical signals that pass along the nerves of the body, to treat disorders as diverse as inflammatory bowel disease, arthritis, asthma, hypertension and diabetes.”
For the majority of drugs, end-of-lifecycle planning usually involves a reining-in of marketing costs. But Sucampo CEO Peter Greenleaf is doing the exact opposite. In the firm’s second-quarter earnings call, he announced the company is “doubling-down” on Amitiza, the constipation treatment which has been on the market for eight years and which will soon face the threat of generic competition.
Amitiza owns just 1% of the overall constipation market, which includes a number of OTC options, a representative for the drugmaker told MM&M. Sucampo co-markets Amitiza with Takeda.
The University of Central Florida’s Business Incubation Program has pumped nearly $2.5 billion into the economy over the last 15 years.
The program — which turns 15 years old on Oct. 1 — has created 250 early-stage companies, according to a press release sent out Sept. 30. Those companies have added 3,600 total jobs, sales of $1.51 billion and $2.48 billion in regional economic output.
The White House said that President Obama’s BRAIN Initiative is generating interest from companies and philanthropies in a sign of what it calls a wider partnership developing around the U.S. administration’s most prominent science initiative, first unveiled in 2013.
The White House had committed to spending $100 million this year on the project, which seeks to develop new technologies for studying the brain. As part of that, today the U.S. National Institutes of Health announced $46 million in awards to 58 research groups.
Baxter International Inc. (NYSE:BAX) today announced plans to form a new global innovation and research and development (R&D) center in Cambridge, Mass., for Baxter’s biopharmaceuticals business, which is expected to become a separate, independent global company known as Baxalta Incorporated in mid-2015.
The business selected the Cambridge biotech community as the primary location for its global innovation and R&D operations after a global search. The new location will position the company to enhance patient care by advancing and building its robust innovation pipeline, which is centered on core areas of expertise in hematology, immunology, and through technology platforms like gene therapy and biosimilars.
Limited partners are actively returning to venture capital and many are looking beyond the industry’s giants. “I think this is the first year that LPs have realized that you can make a lot of money in small venture funds as well,” said Hans Swildens, founder and CEO of Industry Ventures.
The firm has closed on $170 million, more than twice the size of its previous fund, for a fund of funds targeting venture capital funds of less than $250 million. That’s another sign of rising investor interest in these smaller pools, Russ Garland reports for Dow Jones VentureWire.
The year 2014 has not just started out on a good note for the digital health and health IT market, but it seems to be all set to be the best year ever. The top 20 venture capital firms have been busy right from the start of the year investing in this arena and giving a massive boost to deal activity here. A CB Insights data report indicates that funding to the tune of $2.65 billion has come into this sector over the past four quarters. What is even more significant is that the highest quarterly funding amount came about in Q1 of this year. With investors deploying $1,108.6 million over the first three months of 2014, this quarter has witnessed a whopping 210% increase in funding when compared with the same period last year.
As the Obama administration tries to stop companies from avoiding taxes by moving their headquarters overseas, the makers of some of the world’s most lucrative and expensive medicines are using another tactic to reduce their payments to the government.
Take the case of Gilead Sciences, which has come under severe criticism for the high cost of its in-demand new hepatitis C drug, Sovaldi, which sells for $1,000 a pill, or $84,000 for a typical course of treatment.
